REGN - Regeneron Pharmaceuticals, Inc. -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg · closes rebased to 100 at each year's first session
Ticker Details
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals Inc is an integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
IPO Date: April 2, 1991
Sector: Healthcare
Industry: Biotech
Market Cap: $76.4B
Activated in VL: True
Average Daily Range
Avg Daily Range: $4.77 | 1.89%
Avg Daily Range (30 D): $10.96 | 1.38%
Avg Daily Range (90 D): $9.96 | 1.38%
Institutional Daily Volume
Avg Daily Volume: .67M
Avg Daily Volume (30 D): .47M
Avg Daily Volume (90 D): .58M
Trade Size
Avg Trade Size (Sh.): 58
Avg Trade Size (Sh.) (30 D): 18
Avg Trade Size (Sh.) (90 D): 20
Institutional Trades
Total Institutional Trades: 12,595
Avg Institutional Trade: $19.94M
Avg Institutional Trade (30 D): $71.31M
Avg Institutional Trade (90 D): $59.96M
Avg Institutional Trade Volume: .05M
Avg Institutional Trades (Per Day): 2
Market Closing Trades
Avg Closing Trade: $41.03M
Avg Closing Trade (30 D): $135.95M
Avg Closing Trade (90 D): $132.93M
Avg Closing Volume: 78.83K
 
News
Oct 8, 2026 @ 3:21 PM
Bayer Seeks Kerendia Label Expansion in Non-Diabet...
Source: Na
Oct 6, 2026 @ 9:36 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Cl...
Source: Pomerantz Llp
Oct 6, 2026 @ 11:00 AM
Regeneron Showcases Advances in Care Across Severa...
Source: Regeneron Pharmaceuticals, Inc.
Oct 6, 2026 @ 5:30 AM
Press Release : Availability of the aide-mémoir...
Source: Sanofi
Oct 6, 2026 @ 5:30 AM
Communiqué de presse : Mise en ligne du documen...
Source: Sanofi
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $41.91 $12.62 $6.99
Diluted EPS $40.44 $12.23 $6.75
Revenue $15.53B $4.29B $3.61B
Gross Profit
Net Income / Loss $4.33B $1.3B $727.2M
Operating Income / Loss $3.84B $1.29B $642.9M
Cost of Revenue
Net Cash Flow $450.4M $-504.6M $-153.1M
PE Ratio